Sanofi raises profit outlook after strong second quarter
French drugmaker posts nearly €9bn in revenue for the quarter
Paris — Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment helped it beat second-quarter results expectations.
The French drugmaker said it was now targeting earnings per share growth of about 12% at constant exchange rates in 2021, up from “high single digit” percentage growth previously.
Sanofi, which shocked investors in 2020 with a delay to a Covid-19 vaccine it is developing with Britain’s GlaxoSmithKline , reiterated its confidence in the shot, which it hopes will secure regulatory approval by the end of the year.
Europe’s drug regulator said last week it had started a real-time review of the vaccine.
If approved, Sanofi’s shot will come long after ones from Pfizer/BioNTech, and Moderna, which have produced efficacy results of more than 90%.
But the French company believes its vaccine could play a significant role in tackling the pandemic, as many parts of the world still have a pressing need for doses.
In countries already rolling out mass vaccinations, Sanofi also sees a potential role for the shot as a booster, as many regulators contemplate recommending a third dose to extend protection.
So far, Sanofi has purchasing agreements with the US, the EU, Britain and Canada, as well as with the World Health Organization-backed Covax facility.
The company has also pledged to help other Covid-19 vaccine makers in 2021, striking “fill and finish” deals for shots made by Pfizer/BioNTech, Moderna and Johnson & Johnson.
Sales of Dupixent, which is sold to patients with eczema but also prescribed for other conditions such as asthma, jumped 57% to €1.24bn.
Revenue at the vaccines unit was up 16.2% to €1bn, helped by stronger demand for booster and meningitis shots.
Overall, Sanofi’s sales rose 12.4% in the second quarter to €8.74bn, while business net income — a figure the company uses as its core metric to measure profits — was up 16.8% to €1.73bn.
Analysts polled by Refinitiv had on average been expecting sales of €8.5bn and net income of €1bn.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.